Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium

Published:2020-12-22 Issue:2 Volume:10 Page:447-453
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Komrokji Rami S.¹^ORCID,Al Ali Najla H¹,Sallman David¹^ORCID,Padron Eric¹,DeZern Amy E.²,Barnard John³,Roboz Gail J.⁴,Garcia‐Manero Guillermo⁵,List Alan¹,Steensma David P.⁶,Sekeres Mikkael A.⁷

Affiliation:

1. Malignant Hematology Department H Lee Moffitt Cancer Center and Research Institute Tampa FL USA

2. Kimmel Cancer Center/Johns Hopkins University Baltimore MD USA

3. Department of Quantitative Health Sciences Cleveland Clinic Cleveland OH USA

4. Weill Cornell Medical College New York NY USA

5. Department of Leukemia MD Anderson Cancer Center Houston TX USA

6. Dana‐Farber Cancer Institute Boston MA USA

7. Leukemia Program Cleveland Clinic Cleveland OH USA

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3608

Reference11 articles.

1. Current state of prognostication and risk stratification in myelodysplastic syndromes

2. Report of an international working group to standardize response criteria for myelodysplastic syndromes;Cheson BD;Blood,2000

3. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

4. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML;Clinical Epigenetics;2024-06-15

2. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML;Blood Neoplasia;2024-06

3. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML;2024-03-21

4. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial;The Lancet Haematology;2024-01

5. Frontline treatment options for higher-risk MDS: can we move past azacitidine?;Hematology;2023-12-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3